Immunic, Inc.

NASDAQ:IMUX

Biotechnology

Healthcare
$7.52 -0.28%

-$0.04 today

Market cap
$102.61M
Beta
1.39
P/E (TTM)
-4.1
EPS (TTM)
-$3.46
52W Low $5.06High $15.77

Volume 0.17M

Average 0.27M

IMUX EBITDA Margin

EBITDA as a percentage of revenue.

Immunic, Inc.NASDAQ: IMUX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How IMUX compares with its peers on the latest reported figures

IMUX Competitors Peer median
EBITDA Margin for IMUX and competitors
Company Period LTM level YoY 3-year change
VXRTVaxart, Inc.LTM Mar 202618.5% +115.0 pp+94012.8 pp
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1298.7% +1519.2 pp-759.6 pp
CBUSCibus, Inc.LTM Mar 2026-1453.8% +4107.2 pp+7193.6 pp
IMUXImmunic, Inc.FY2025— ——
RLMDRelmada Therapeutics, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding IMUX) -1298.7%+1519.2 pp+7193.6 pp

Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development61.12M71.26M83.22M80.05M81.98M
Selling, General & Admin13.3M15.26M16.01M18.01M21.25M
Operating Expenses91.67M119.49M99.22M98.05M103.23M
Depreciation & Amortization85K77K111K134K168K
EBITDA(92.86M)(86.44M)(93.5M)(100.37M)(97M)
EBITDA Margin—————
Operating Income(91.67M)(119.49M)(99.22M)(98.05M)(103.23M)
Operating Margin—————
Interest Income66K1.04M3.08M3.39M1.04M
Interest Expense01.04M000
Other Income / Expenses(1.28M)(919K)5.61M(2.46M)6.06M
Income Before Tax(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Net Margin—————
EPS (Basic)(39.20)(37.80)(21.10)(10.00)(6.24)
EPS (Diluted)(39.20)(37.80)(21.10)(10.00)(6.24)
Weighted Avg Shares2.37M3.18M4.43M10.02M15.57M
Weighted Avg Shares (Diluted)2.37M3.18M4.43M10.02M15.57M

Immunic, Inc.

NASDAQ:IMUX

Intrinsic Alpha fair value

Locked

Current Price

$7.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.